The news of HC Wainwright & Co. maintaining a Buy rating on Arcadia Biosciences is positive for the stock. However, the lowering of the price target from $18 to $15 may create some uncertainty among investors, potentially offsetting the positive sentiment. As a result, the short-term impact on the stock price is expected to be neutral.